Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BRS3 | P32247 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14639731 | 1.00 | KDM4E (0.34) | KDM4EALDH1A1POLBBRS3MTNR1B | |
| SCHEMBL643400 | 0.79 | NR1H3 (0.44) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10174355 | 0.76 | SMN1; SMN2 (0.37) | KDM4EALDH1A1POLBMTNR1BSMN1; SMN2 | |
| SCHEMBL14639709 | 0.76 | SMN1; SMN2 (0.37) | KDM4EALDH1A1POLBMTNR1BSMN1; SMN2 | |
| SCHEMBL23488614 | 0.72 | L3MBTL1 (0.43) | PIK3CD | |
| SCHEMBL17788020 | 0.71 | OPRK1 (0.35) | ALDH1A1POLBMTNR1BSMN1; SMN2HHAT | |
| SCHEMBL3080868 | 0.71 | PREP (0.47) | SMN1; SMN2 | |
| SCHEMBL15817780 | 0.70 | DPP4 (0.42) | POLBBRS3PIK3CDDPP4DPP8 | |
| SCHEMBL13218350 | 0.69 | FAP (0.42) | DPP4DPP8DPP9 | |
| SCHEMBL13532952 | 0.69 | FAP (0.42) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023710-A1 | Compound | NR1H3, NR1H2, NR1H4 | KDM4E 2751/4885ALDH1A1 2109/4885POLB 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.